載入...
Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
BACKGROUND: Glucose variability has been associated with cardiovascular outcomes in type 2 diabetes, however, the interplay between glucose variability, empagliflozin and cardiovascular death has not been explored. In the EMPA-REG OUTCOME trial, empagliflozin reduced the risk of cardiovascular death...
Na minha lista:
| 發表在: | Cardiovasc Diabetol |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7556977/ https://ncbi.nlm.nih.gov/pubmed/33050931 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01147-9 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|